🚨 Exciting news! 🚨 #SABCS24 is almost here, and I'm thrilled to share that 50 #ILC #Lobular abstracts will be presented this year! 📚✨ This is a major milestone—just a few years ago, we barely saw single-digit numbers. The progress is incredible! Huge kudos to @LobularBCA, @elbcc, @LobularBCUK, and @LobularIreland for championing this progress! 👏👏👏 @SABCSSanAntonio @AACR @OncoAlert @oncodaily

5 #ILC Abstracts will be presented at #ASCO24 as Poster Presentations on Sunday June 2nd at 9:00 AM - 12:00 PM 1️⃣ Racial disparities in presentation and survival for lobular breast cancer Presenter: @SimranSandhu17_ (University of Galway, Ireland); @DavidLimMD Data: SEER database study with 38,769 ILC patients Findings: Black women present with more advanced disease; Asian women are younger at diagnosis. 5-year overall survival for Black women is worse. Takeaway: We must bridge the gaps in care for ILC patients across different races. 2️⃣ The multiomic tumor microenvironment landscape of ILC Presenter: @JAMouabbi (MD Anderson Cancer Center) @BostonGeneCorp @Hensley1552 Data: MxIF on 2,139,084 cells from FFPE whole-slide tissues Findings: Detailed multiomic analysis reveals 40% of ILC samples are immune enriched (potential for immunotherapy) and 30% are highly vascularized (potential for anti-angiogenesis therapy). Takeaway: Many ILC patients may benefit from immunotherapy or anti-angiogenesis regimens. 3️⃣ Neoadjuvant targeted therapy in HER2-mutant lobular breast cancer Presenter: Laura Kennedy (Vanderbilt-Ingram Cancer Center); @AriellaHanker @CarlosArteagaMD Background: 10% of ILCs have HER2 (ERBB2) mutations, linked to ET resistance and worse prognosis. Study: NCT05919108, Phase II trial for 30 patients with Stage I-III ILC and HER2 mutation, receiving letrozole + neratinib for 6 months pre-surgery. 4️⃣ Transcriptomic analysis of cAMP/PKA/CREB signaling in ILC Presenter: @Susruthapn (Washington University School of Medicine); @oesterreichs Data: RNA-seq from three large breast cancer databases Findings: Up-regulation of cAMP/PKA/CREB signaling in ILC compared to NST/IDC. Takeaway: Unique signaling pathway in ILC could lead to novel therapeutic targets. 5️⃣ Clinical-pathological characteristics and multigene assay risk scores in ILC Presenter: Young-Won Lee (University of Ulsan College of Medicine, Seoul, Korea); @AsanMedicalCtr Data: Retrospective analysis of 238 ILC cases Findings: Predictive factors for ODX recurrence score in ILC differ from IDC. Takeaway: Need for ILC-specific risk prediction tools. #bcsm #EndCancer #ILC @LobularBCA @LobularBCUK @LobularIreland @lobbccanada @elbcc @double_whammied @lbhutcheson @OncoAlert @ASCO @VJOncology @OncBrothers @OncData @Keira_OncData

If you couldn’t attend our @MDAndersonNews #ILC educational session at @SABCSSanAntonio #SABC23, explore the meticulous masterpiece provided by @CBankheadMPT in this insightful @medpagetoday article. It comprehensively delves into the session, presenting a well-crafted and engaging overview. Kudos to the organizing committee for allocating a session to discuss #ILC, and sincere appreciation to @LobularBCA for sponsoring and actively promoting additional #ILC sessions in both national and international oncology conferences. Congratulations to my colleagues @ChristineDesme2 and @TariKingMD for their insightful presentations, and special acknowledgment to the #MotherofILC @oesterreichs, and @BreastDense for expertly co-chairing the session. medpagetoday.com/clinical-ch… – at Houston, TX